vs
STANDARD BIOTOOLS INC.（LAB）与Veritone, Inc.（VERI）财务数据对比。点击上方公司名可切换其他公司
Veritone, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.4倍（$26.6M vs $19.6M），Veritone, Inc.净利率更高（-109.8% vs -177.4%，领先67.6%），Veritone, Inc.同比增速更快（21.1% vs -11.5%），Veritone, Inc.自由现金流更多（$-17.1M vs $-23.1M），过去两年Veritone, Inc.的营收复合增速更高（39.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Veritone公司是2014年成立的美国人工智能科技企业，总部位于加利福尼亚州欧文市。公司业务覆盖多个领域，服务对象包含媒体机构、职业体育俱乐部、联邦政府机构、能源公用事业企业以及各级地方警务部门。
LAB vs VERI — 直观对比
营收规模更大
VERI
是对方的1.4倍
$19.6M
营收增速更快
VERI
高出32.6%
-11.5%
净利率更高
VERI
高出67.6%
-177.4%
自由现金流更多
VERI
多$6.0M
$-23.1M
两年增速更快
VERI
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $26.6M |
| 净利润 | $-34.7M | $-29.2M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -68.2% |
| 净利率 | -177.4% | -109.8% |
| 营收同比 | -11.5% | 21.1% |
| 净利润同比 | -28.8% | -34.5% |
| 每股收益（稀释后） | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABVERI
| Q3 25 | $19.6M | $26.6M | ||
| Q2 25 | $21.8M | $23.2M | ||
| Q1 25 | $40.8M | $22.5M | ||
| Q4 24 | — | $22.4M | ||
| Q3 24 | $22.1M | $22.0M | ||
| Q2 24 | $22.5M | $24.1M | ||
| Q1 24 | $45.5M | $24.2M | ||
| Q4 23 | $28.2M | $13.8M |
净利润LABVERI
| Q3 25 | $-34.7M | $-29.2M | ||
| Q2 25 | $-33.5M | $-26.5M | ||
| Q1 25 | $-26.0M | $-19.9M | ||
| Q4 24 | — | $31.8M | ||
| Q3 24 | $-26.9M | $-21.7M | ||
| Q2 24 | $-45.7M | $-22.2M | ||
| Q1 24 | $-32.2M | $-25.2M | ||
| Q4 23 | $-19.8M | $12.2M |
毛利率LABVERI
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | 72.6% | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | 71.2% | ||
| Q2 24 | 46.1% | 72.6% | ||
| Q1 24 | 53.1% | 70.8% | ||
| Q4 23 | 47.6% | 51.7% |
营业利润率LABVERI
| Q3 25 | -168.5% | -68.2% | ||
| Q2 25 | -118.1% | -82.0% | ||
| Q1 25 | -80.8% | -96.3% | ||
| Q4 24 | — | -93.8% | ||
| Q3 24 | -120.9% | -102.3% | ||
| Q2 24 | -134.5% | -84.4% | ||
| Q1 24 | -132.2% | -100.9% | ||
| Q4 23 | -75.9% | -164.0% |
净利率LABVERI
| Q3 25 | -177.4% | -109.8% | ||
| Q2 25 | -153.7% | -114.2% | ||
| Q1 25 | -63.8% | -88.5% | ||
| Q4 24 | — | 141.7% | ||
| Q3 24 | -122.0% | -98.9% | ||
| Q2 24 | -203.3% | -92.4% | ||
| Q1 24 | -70.6% | -104.3% | ||
| Q4 23 | -70.2% | 88.3% |
每股收益（稀释后）LABVERI
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | $-0.53 | ||
| Q1 25 | $-0.07 | $-0.41 | ||
| Q4 24 | — | $0.85 | ||
| Q3 24 | $-0.07 | $-0.57 | ||
| Q2 24 | $-0.12 | $-0.59 | ||
| Q1 24 | $-0.27 | $-0.67 | ||
| Q4 23 | $-0.24 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $36.2M |
| 总债务越低越好 | — | $35.4M |
| 股东权益账面价值 | $399.7M | $15.5M |
| 总资产 | $539.6M | $198.6M |
| 负债/权益比越低杠杆越低 | — | 2.28× |
8季度趋势，按日历期对齐
现金及短期投资LABVERI
| Q3 25 | $129.4M | $36.2M | ||
| Q2 25 | $158.6M | $13.6M | ||
| Q1 25 | $150.9M | $16.1M | ||
| Q4 24 | — | $16.9M | ||
| Q3 24 | $210.6M | $11.4M | ||
| Q2 24 | $269.8M | $46.0M | ||
| Q1 24 | $287.1M | $90.7M | ||
| Q4 23 | $51.7M | $46.6M |
总债务LABVERI
| Q3 25 | — | $35.4M | ||
| Q2 25 | — | $37.3M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | $55.2M | $73.6M | ||
| Q2 24 | $55.1M | $75.6M | ||
| Q1 24 | $55.0M | $77.5M | ||
| Q4 23 | $63.5M | $77.5M |
股东权益LABVERI
| Q3 25 | $399.7M | $15.5M | ||
| Q2 25 | $424.5M | $3.5M | ||
| Q1 25 | $454.6M | $14.8M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $489.3M | $-25.2M | ||
| Q2 24 | $510.3M | $-5.7M | ||
| Q1 24 | $577.3M | $14.9M | ||
| Q4 23 | $-148.1M | $38.1M |
总资产LABVERI
| Q3 25 | $539.6M | $198.6M | ||
| Q2 25 | $557.0M | $188.1M | ||
| Q1 25 | $579.6M | $199.6M | ||
| Q4 24 | — | $198.1M | ||
| Q3 24 | $681.5M | $336.4M | ||
| Q2 24 | $708.7M | $321.8M | ||
| Q1 24 | $777.7M | $359.6M | ||
| Q4 23 | $323.1M | $378.9M |
负债/权益比LABVERI
| Q3 25 | — | 2.28× | ||
| Q2 25 | — | 10.71× | ||
| Q1 25 | — | 2.66× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | 5.21× | ||
| Q4 23 | — | 2.03× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-15.9M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-17.1M |
| 自由现金流率自由现金流/营收 | -118.1% | -64.2% |
| 资本支出强度资本支出/营收 | 4.5% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-46.4M |
8季度趋势，按日历期对齐
经营现金流LABVERI
| Q3 25 | $-22.2M | $-15.9M | ||
| Q2 25 | $-20.7M | $-8.2M | ||
| Q1 25 | $-30.3M | $-17.0M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-27.9M | $3.6M | ||
| Q2 24 | $-39.0M | $-42.7M | ||
| Q1 24 | $-62.5M | $14.9M | ||
| Q4 23 | $-14.1M | $-28.3M |
自由现金流LABVERI
| Q3 25 | $-23.1M | $-17.1M | ||
| Q2 25 | $-22.6M | $-9.2M | ||
| Q1 25 | $-35.3M | $-18.4M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-30.1M | $1.9M | ||
| Q2 24 | $-41.0M | $-44.1M | ||
| Q1 24 | $-63.3M | $13.1M | ||
| Q4 23 | $-14.1M | $-29.0M |
自由现金流率LABVERI
| Q3 25 | -118.1% | -64.2% | ||
| Q2 25 | -103.6% | -39.6% | ||
| Q1 25 | -86.6% | -81.9% | ||
| Q4 24 | — | -7.4% | ||
| Q3 24 | -136.4% | 8.6% | ||
| Q2 24 | -182.2% | -183.4% | ||
| Q1 24 | -138.9% | 54.2% | ||
| Q4 23 | -50.2% | -210.2% |
资本支出强度LABVERI
| Q3 25 | 4.5% | 4.6% | ||
| Q2 25 | 8.7% | 4.1% | ||
| Q1 25 | 12.4% | 6.0% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | 10.2% | 7.7% | ||
| Q2 24 | 8.6% | 5.9% | ||
| Q1 24 | 1.7% | 7.6% | ||
| Q4 23 | 0.3% | 4.9% |
现金转化率LABVERI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.02× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
VERI
| Software Products And Services | $20.9M | 78% |
| Other | $2.3M | 9% |
| Public Sector | $2.0M | 7% |
| Representation Services | $1.5M | 6% |
